

Carta Trámite

12 de marzo de 2020

A: Todos los Proveedores Contratados por First Medical Health Plan, Inc. para el Plan Vital, Región Única y Población Vital-X (Virtual)

Re: Carta Normativa 20-0311 de la Administración de Seguros de Salud de Puerto Rico, relacionada a la Cubierta de Beneficios del Coronavirus (COVID-19)

Estimado(a) Proveedor(a):

Reciba un cordial saludo de parte de First Medical Health Plan, Inc.

Adjunto a este comunicado encontrará la Carta Normativa 20-0311 de la Administración de Seguros de Salud de Puerto Rico (ASES), emitida el 11 de marzo de 2020.

A través de este comunicado, la ASES informa que, la cubierta de beneficios del Plan Vital incluye las pruebas de laboratorio ordenadas por un médico para el diagnóstico del coronavirus (COVID-19). Los proveedores y laboratorios que realicen las pruebas de COVID-19 a los beneficiarios del Plan Vital, deberán utilizar el código (U0001).

Para detalles específicos sobre la información provista por la ASES, le exhortamos a que lea detenidamente la Carta Normativa 20-0311.

Si usted tiene alguna pregunta relacionada a este comunicado y/o necesita información adicional, siéntase en la libertad de comunicarse con nuestro Centro de Servicio al Proveedor al número libre de cargos 1-844-347-7802 de lunes a viernes de 7:00 a.m. a 7:00 p.m. También, puede acceder a nuestra página electrónica www.firstmedicalvital.com.

Cordialmente,

Departamento de Cumplimiento
First Medical Health Plan, Inc.



GOBIERNO DE PUERTO RICO
Administración de Seguros de Salud

Normative Letter 20-0311

March 11, 2020

To: Managed Care Organizations (MCO's) contracted to offer services under the Government Health Plan Program (Plan Vital); Primary Care Physicians (PCP), Primary Medical Groups (PMG) and participants providers

Re: Coverage and Benefits Related to COVID-19

Plan Vital provides a comprehensive health coverage to 1.2 million of beneficiaries in Puerto Rico, including Medicaid, Children's Health Insurance Program (CHIP), Commonwealth and Dual Eligible (Medicare Part A, AB - Medicaid).

The purpose of this communication is to clarify that Plan Vital covers a broad range of benefits, which include as a mandatory requirement by the Center for Medicare and Medicaid Services (CMS), the laboratory services ordered by the physician.

Recently, CMS developed a new Healthcare Common Procedure Coding System (HCPCS) code for providers and laboratories to test patients for Coronavirus (COVID-19). As CMS mentioned in the attached release, the provider who needs to test a patient for Coronavirus Real Time RT-PCP Diagnostic Test Panel may bill it using the (U0001).

Accordingly, all the MCO's must modify the in claims system in order to process the bills submitted by providers and to closely monitor claims payments. No copay for this service will apply to the beneficiary, irrespective of what type of coverage they have.

Cordially,


Jorge E. Galva, JD, MHA
Executive Director



• PO Box 195661, San Juan, PR 00919-5661 • Tel: 787.474.3300 • www.asespr.org

Autorizado por la Comisión Estatal de Elecciones CEE-SA-19-166

Newsroom

Press release

Q Search newsroom articles

CMS Develops Additional Code for Coronavirus Lab Tests

Mar 05, 2020 | Coding, Clinical labs

Share

Agency Issues Fact Sheets Detailing Coverage under Programs

Today, the Centers for Medicare & Medicaid Services (CMS) took additional actions to ensure America's patients, healthcare facilities and clinical laboratories are prepared to respond to the 2019-Novel Coronavirus (COVID-19).

CMS has developed a second Healthcare Common Procedure Coding System (HCPCS) code that can be used by laboratories to bill for certain COVID-19 diagnostic tests to help increase testing and track new cases. In addition, CMS released new fact sheets that explain Medicare, Medicaid, Children's Health Insurance Program, and Individual and Small Group Market Private Insurance coverage for services to help patients prepare as well.

"CMS continues to leverage every tool at our disposal in responding to COVID-19," said CMS Administrator Seema Verma. "Our new code will help encourage doctors and laboratories to use these essential tests for patients who need them. At the same time, we are providing critical information to our 130 million beneficiaries, many of whom are understandably wondering what will be covered when it comes to this virus. CMS will continue to devote every available resource to this effort, as we cooperate with other government agencies to keep the American people safe."

HCPCS is a standardized coding system that Medicare and other health insurers use to submit claims for services provided to patients. Last month, CMS developed the first HCPCS code (U0001) to bill for tests and track new cases of the virus. This code is used specifically for CDC testing laboratories to test patients for SARS-CoV-2. The second HCPCS billing code (U0002) announced today allows laboratories to bill for non-CDC laboratory tests for SARS-CoV-2/2019-nCoV (COVID-19). On February 29, 2020, the Food and Drug Administration (FDA) issued a new, streamlined policy for certain laboratories to develop their own validated COVID-19 diagnostics. This second HCPCS code may be used for tests developed by these additional laboratories when submitting claims to Medicare or health insurers. CMS expects that having specific codes for these tests will encourage testing and improve tracking.

The Medicare claims processing systems will be able to accept these codes starting on April 1, 2020, for dates of service on or after February 4, 2020. Local Medicare Administrative Contractors (MACs) are responsible for developing the payment amount for claims they receive for these newly created HCPCS codes in their respective jurisdictions until Medicare establishes national payment rates. Laboratories may seek guidance from their MAC on payment for these tests prior to billing for them. As with other laboratory tests, there is generally no beneficiary cost sharing under Original Medicare.

To ensure the public has clear information on coverage and benefits under CMS programs, the agency also released three fact sheets that cover diagnostic laboratory tests, immunizations and vaccines, telemedicine, drugs, and cost-sharing policies.

Medicare Fact Sheet Highlights: In addition to the diagnostic tests described above, Medicare covers all medically necessary hospitalizations, as well as brief “virtual check-ins,” which allows patients and their doctors to connect by phone or video chat.

Medicaid and Children’s Health Insurance Program (CHIP) Fact Sheet Highlights: Testing and diagnostic services are commonly covered services, and laboratory and x-ray services are a mandatory benefit covered and reimbursed in all states. States are required to provide both inpatient and outpatient hospital services to beneficiaries. All

states provide coverage of hospital care for children and pregnant women enrolled in CHIP. Specific questions on covered benefits should be directed to the respective state Medicaid and CHIP agency.

Individual and Small Group Market Insurance Coverage: Existing federal rules governing health insurance coverage, including with respect to viral infections, apply to the diagnosis and treatment of with Coronavirus (COVID-19). This includes plans purchased through HealthCare.gov. Patients should contact their insurer to determine specific benefits and coverage policies. Benefit and coverage details may vary by state and by plan. States may choose to work with plans and issuers to determine the coverage and cost-sharing parameters for COVID-19 related diagnoses, treatments, equipment, telehealth and home health services, and other related costs.

Summary of CMS Public Health Action on COVID-19 to date:

On March 4, 2020, CMS issued a call to action to healthcare providers nationwide to ensure they are implementing longstanding infection control procedures and issued important guidance to help State Survey Agencies and Accrediting Organizations prioritize their inspections of healthcare facilities to focus exclusively on issues related to infection control and other serious health and safety threats. For more information on CMS actions to prepare for and respond to COVID-19, visit: <https://www.cms.gov/newsroom/press-releases/cms-announces-actions-address-spread-coronavirus>

On February 13, 2020, CMS issued a new HCPCS code for healthcare providers and laboratories to test patients for COVID-19 using the CDC-developed test. For more information about this code, visit: <https://www.cms.gov/newsroom/press-releases/public-health-news-alert-cms-develops-new-code-coronavirus-lab-test>

On February 6, 2020, CMS issued a memo to help the nation's healthcare facilities take critical steps to prepare for COVID-19. To view a copy of the memo and see more details, visit: <https://www.cms.gov/medicareprovider-enrollment-and-certificationsurveycertificationgeninfopolicy-and-memos-states-and/information-healthcare-facilities-concerning-2019-novel-coronavirus-illness-2019-ncov>

On February 6, 2020, CMS also gave CLIA-certified laboratories information about how they can test for SARS-CoV-2. To read more about those efforts, visit: <https://www.cms.gov/medicareprovider-enrollment-and-certificationsurveycertificationgeninfopolicy-and-memos-states-and/notification-surveyors-authorization-emergency-use-cdc-2019-novel-coronavirus-2019-ncov-real-time-rt>

For the updated information on the range of CMS activities to address COVID-19, visit: <https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/Current-Emergencies/Current-Emergencies-page>

###

Get CMS news at [cms.gov/newsroom](https://www.cms.gov/newsroom), sign up for CMS news [via email](#) and follow CMS on Twitter CMS Administrator [@SeemaCMS](#), [@CMSgov](#), and [@CMSgovPress](#).

[← Previous](#)

[Next →](#)

Get email updates

Sign up to get the latest information about your choice of CMS topics in your inbox. Also, you can decide how often you want to get updates.

SIGN UP

7500 Security Boulevard, Baltimore, MD 21244

